Navigation Links
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Date:1/15/2009

ram is an embedded part of our company's culture. These are not just words to us - we continue to implement a range of programs and policies to help ensure that we operate in a manner consistent with all applicable laws and regulations. These programs apply to all parts of our business, and all of our employees are aware of the imperative for them to be models of compliance and of ethical behavior."

The misdemeanor plea is for the off-label promotion of Zyprexa between September of 1999 and March of 2001. Specifically, the plea states that Lilly promoted Zyprexa in elderly populations as treatment for dementia, including Alzheimer's dementia, although Zyprexa is not approved for such uses. As part of this agreement regarding the criminal investigation, Lilly has agreed to pay $615 million.

Under terms for the resolution of the civil investigations, Lilly has agreed to make payments totaling nearly $800 million. Approximately $438 million will be paid to the federal government and approximately $362 million will be made available for payment to settling states. As previously reported, Lilly took a charge of $1.415 billion, or $1.29 per share, in the third quarter of 2008 in connection with this investigation. The 2008 charge will be sufficient to cover the payments announced today. The company is now finalizing the tax treatment of these payments, and will communicate this impact when the company announces fourth quarter 2008 financial results on January 29, 2009.

Lilly has a comprehensive compliance program that is designed to ensure that the company's global business practices fully comply with all laws and regulations. Lilly's compliance program, which the company is committed to continually improving and enhancing, includes each of the elements of compliance guidelines issued by the Department of Health and Human Services, Office of Inspector General, for the pharmaceutical industry. The co
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition
2. Lilly Sets Date and Conference Call for Fourth-Quarter and Full-Year 2008 Financial Results Announcement
3. Lilly Announces Dividend Increase
4. Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies
5. Lilly Global Day of Service Receives National and Local Recognition
6. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
7. Lilly Completes Acquisition of ImClone Systems
8. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
9. Lilly Offers Free Health Guide, Available throughout State
10. Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center
11. Lilly Announces Major Donation of Insulin to International Diabetes Federations Life for a Child Program; Initial Focus Will Be on Sub-Saharan Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... the year for the latest science in the field. ... Care Association (ACCA) of the European Society of Cardiology ... , Monday 16 September 2014 Sophia Antipolis, France ... dealing with acute problems in need of urgent care ... The scientific programme is available here . , ...
(Date:9/16/2014)... This news release is available in French . ... of a healthy diet and dietary guidelines recommend the daily ... yogurt, cheese, cream and butter. , It,s well ... bones, but new research has shown that dairy consumption may ... risk of metabolic diseases such as obesity and type 2 ...
(Date:9/16/2014)... Angeles, CA (PRWEB) September 16, 2014 According ... NFL player David Wilson has retired after aggravating a neck ... disc, and was then discovered to have spinal stenosis as ... affects many adults and can lead to symptoms such as ... could play again after surgery to repair the disc, but ...
(Date:9/16/2014)... NEW YORK (PRWEB) September 16, 2014 Today ... announced that its annual “Festive Evening of Song,” featuring luminary ... will take place on Monday, September 29, 2014 at the ... in Tarrytown, New York. The FSH Society is proud to ... event aimed at raising funds for FSHD research. , FSHD, ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 According to ... leading global authority in medical device market research, the ... over $750 million in the U.S . and ... initial PEG placement kits, PEG replacement tubes, DPEJ tubes, ... segmented into low-profile balloon tubes, low-profile non-balloon tubes, nasogastric ...
Breaking Medicine News(10 mins):Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 2Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 3Health News:More cheese, please! News study shows dairy is good for your metabolic health 2Health News:NFL Injuries Put Spotlight on Spinal Health 2Health News:NFL Injuries Put Spotlight on Spinal Health 3Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3
... Dana-Farber Cancer Institute in Boston, Massachusetts has come out ... monitored, prescribed and// coordinated in a better way. ... the institutes that participated in the research, Dr Lawrence ... the importance of forging a consensus in the oncology ...
... Canadian Institute of Health Research, in collaboration with Heart ... and women react// differently to medications for their heart ... by Canadian GENESIS project, men's ailing hearts respond differently ... Angiograms, which are usually effective in pinpointing heart problems ...
... the onset of dementia”, claims a research report. This study ... Toronto, Canada on 184 elderly patients. ... remaining spoke only one language. The average age in the ... was 71.4 in the other group. The study had considered ...
... you looking for simple ways to improve your heart health? ... or sprinkled throughout your day, may be one easy and// ... almonds continues to show why including a handful of almonds ... a look at what they are finding. ,Almonds ...
... specific health care should be provided for British Muslims. Professor ... the key for better health for Muslims in United Kingdom. ... Journal, professor reiterates the need for academicians, doctors and policy ... in the existing system. ,A provision for ...
... heart disease is a two-way street: Poor sleep can ... sleep, reports the January 2007// issue of the Harvard ... with high blood pressure, atherosclerosis, heart failure, heart attack ... these together may be inflammation, the body’s response to ...
Cached Medicine News:Health News:Watchdog to Be Set on Oral Chemotherapy, Warns Experts 2Health News:Be True to Your Heart With a Handful of Almonds 2Health News:Be True to Your Heart With a Handful of Almonds 3
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
(Date:9/16/2014)... 2014  Eli Lilly and Company (NYSE: ... agreement to co-develop and commercialize AZD3293, an oral ... development as a potential treatment for Alzheimer,s disease. ... characterized by the accumulation of amyloid plaque in ... the development of beta-amyloid. Inhibiting BACE is expected ...
(Date:9/15/2014)... WHIPPANY, N.J. , Sept. 16, 2014 /PRNewswire/ ... based in Espoo, Finland , ... III trial with ODM-201, an investigational oral androgen ... ARAMIS, evaluates ODM-201 in men with castration-resistant prostate ... levels and no detectable metastases. The trial is ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... and KOS, Greece, June 29, 2007 /PRNewswire/ --,The ... treated patients on REVLIMID (lenalidomide) plus the,steroid dexamethasone ... The data are pooled from two large randomized,controlled ... patients,from nearly 100 clinical sites worldwide. These updated ...
... at the 11th International Myeloma Workshop ... of perifosine in,combination with bortezomib, dexamethasone ... relapsed/refractory multiple,myeloma, and as a single ... NEW YORK, June 29, 2007 /PRNewswire-FirstCall/ ...
Cached Medicine Technology:The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
Inquire...
... at the point of care: , Only 120 ... only 70 L of whole blood (all parameters except ... of sensor cassette , safePICO mixer ensures thorough and ... in 7 seconds) * Not ...
Medicine Products: